Korean Wearable ECG Makers Push Into U.S. With 14-Day Monitoring

The push by Korean wearable ECG makers into the U.S. market illustrates how differing healthcare reimbursement structures can shape corporate strategy. In South Korea, low health insurance reimbursement rates and increased competition reportedly cap domestic growth for these firms. This creates an incentive to seek markets where their technology can achieve greater profitability.

The U.S. market offers a contrasting environment, with long-term continuous ECG testing being a standard practice and a corresponding insurance reimbursement system in place. This makes it an attractive destination for companies like ATsens, which has already begun filling prescriptions and is negotiating with a major hospital chain, and Huinno, which is pursuing a North American strategy through Yuhan USA.

Companies are leveraging their existing overseas successes, such as ATsens' growth in Japan and Seers Technology's supply contract in the United Arab Emirates, to build a foundation for U.S. entry. The focus on 14-day monitoring without battery changes aligns with reported consumer preferences in the U.S. market, where extended monitoring is common for detecting intermittent arrhythmias. The integration of AI for ECG data analysis, as seen with Huinno's MEMO Care solution, suggests a strategy to enhance diagnostic support for clinicians.